title: Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab--a paradoxical effect? A case report.
abstract: The paradoxical adverse effects of tumor necrosis factor-alpha (TNF-alpha) antagonists have been described frequently as a result of the widespread use of these drugs. Among the TNF-alpha blocking agents, few reports exist relating the use of adalimumab in cutaneous sarcoidosis, although all of them show good results. More recently, sarcoidosis onsets have been reported with various TNF-alpha inhibitors. The current case is, to our knowledge, the first to describe the exacerbation of cutaneous lesions of sarcoidosis treated with adalimumab.
authors.affiliation: Centro Hospitalar de Lisboa Central, Santo António dos Capuchos Hospital, Dermatolovenereology Department, Lisbon.
authors.forename: Guida
authors.initials: G
authors.lastname: Santos
authors.affiliation: Centro Hospitalar de Setúbal, São Bernardo Hospital, Setúbal, Portugal.
authors.forename: Lourdes Emerenciano
authors.initials: LE
authors.lastname: Sousa
authors.affiliation: Centro Hospitalar de Lisboa Central, Santo António dos Capuchos Hospital, Lisbon, Portugal.
authors.forename: Alexandre Miguel Bruno Lopes
authors.initials: AM
authors.lastname: João
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D001706:Biopsy; D018450:Disease Progression; D005260:Female; D006801:Humans; D008875:Middle Aged; D012507:Sarcoidosis / Q000188:drug therapy* / Q000473:pathology; D012871:Skin Diseases / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab